NEW YORK, NY / ACCESSWIRE / December 2, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EVA Shareholders Click Here: https://www.zlk.com/pslra-1/enviva-class-action-submission-form?prid=34240&wire=1
EIGR Shareholders Click Here: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34240&wire=1
RENT Shareholders Click Here: https://www.zlk.com/pslra-1/rent-the-runway-loss-submission-form?prid=34240&wire=1
* ADDITIONAL INFORMATION BELOW *
Enviva Inc. (NYSE:EVA)
EVA Lawsuit on behalf of: investors who purchased February 21, 2019 - October 11, 2022
Lead Plaintiff Deadline : January 3, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enviva-class-action-submission-form?prid=34240&wire=1
According to the filed complaint, during the class period, Enviva Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Enviva had misrepresented the environmental sustainability of its wood pellet production and procurement; (ii) Enviva had similarly overstated the true measure of cash flow generated by the Company's platform; (iii) accordingly, Enviva had misrepresented its business model and the Company's ability to achieve the level of growth that defendants had represented to investors; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR)
EIGR Lawsuit on behalf of: investors who purchased March 10, 2021 - October 4, 2022
Lead Plaintiff Deadline : January 9, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eiger-biopharmaceuticals-class-action-lawsuit-submission-form?prid=34240&wire=1
According to the filed complaint, during the class period, Eiger BioPharmaceuticals, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) defendants overstated Eiger's clinical and regulatory drug development expertise; (ii) defendants failed to properly assess, and/or ignored issues with, the design of the TOGETHER study and its ability to support the Emergency Use Authorization ("EUA") for the Company's product candidate, peginterferon lambda ; (iii) there were issues with the conduct of the TOGETHER study and/or the TOGETHER study was not properly designed for the peginterferon lambda EUA in the current context of the pandemic; (iv) as a result, the U.S. Food and Drug Administration was unlikely to approve the submission of a peginterferon lambda EUA; (v) as a result of all the foregoing, peginterferon lambda's regulatory and commercial prospects for the treatment of COVID-19 were overstated; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Rent the Runway, Inc. (NASDAQ:RENT)
This lawsuit is on behalf of all persons or entities who purchased Rent the Runway Class A common stock in or traceable to the Company's October 2021 initial public offering.
Lead Plaintiff Deadline : January 13, 2023
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/rent-the-runway-loss-submission-form?prid=34240&wire=1
According to the filed complaint, (i) Rent the Runway was continuing to face extraordinary business headwinds, such as transportation headwinds and labor wage rate increases, from the COVID-19 pandemic; (ii) Rent the Runway's active subscriber enrollments had sharply decelerated from the growth trajectory represented in the offering documents and, as a result, Rent the Runway was several months away from approaching its pre-pandemic levels of active subscriptions; (iii) Rent the Runway needed to substantially increase marketing and advertising costs from historical figures in order to attempt to grow its active subscriber network; (iv) Rent the Runway was suffering from ballooning fulfillment and transportation costs; and (v) as a result, Rent the Runway was suffering accelerating operational losses at the time of the initial public offering and was far less likely to achieve profitability in the near term, if ever, than represented.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP